

STATE OF THE ART MANAGEMENT OF mCRPC

SUMMIT 2
SINGAPORE

Chairs

Arun Azad, Australia

Ravindran Kanesvaran, Singapore

This educational activity is provided by ESMO
and supported by Astellas.



SUNDAY, 24 NOVEMBER 2019
11:00 – 12:30

- | | |
|-------|---|
| 11:00 | Introduction
<i>Arun Azad, Clayton, Australia</i> |
| 11:05 | mCRPC definition and benefits of treatment
<i>Ravindran Kanesvaran, Singapore</i> |
| 11:15 | Optimal first-line treatment in mCRPC
after either chemo or ARI in mHSPC
<i>Cora Sternberg, New York, NY, USA</i> |
| 11:30 | Changing treatment algorithms in mCRPC:
Role of PARP inhibitors
<i>Arun Azad, Clayton, Australia</i> |
| 11:45 | Is there an optimal sequencing strategy
in mCRPC?
<i>Ben Tran, Melbourne, Australia</i> |
| 12:00 | Immunotherapy in mCRPC management
<i>Arun Azad, Clayton, Australia</i> |
| 12:15 | Conclusion and wrap up
<i>Ravindran Kanesvaran, Singapore</i> |

